Advertisement
BEAM vs SYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and SYRE is a Buy.
BEAM sees its Stochastic Oscillator climbs out of oversold territory
On October 20, 2026, the Stochastic Oscillator for BEAM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 55 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on BEAM as a result. In 70 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on September 29, 2026. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in 45 of 52 cases over the following month. The odds of a continued upward trend are 87%.
Following a +6.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 196 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for BEAM entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.302) is normal, around the industry mean (2.974). P/E Ratio (-34.478) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. BEAM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SYRE in upward trend: price rose above 50-day moving average on October 26, 2026
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 66 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.
Following a +9.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.147) is normal, around the industry mean (2.974). P/E Ratio (-51.603) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BEAM | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 92 | 96 | |
PRICE GROWTH RATING 1..100 | 70 | 35 | |
P/E GROWTH RATING 1..100 | 28 | 42 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as BEAM (6) in the null industry. This means that SYRE’s stock grew similarly to BEAM’s over the last 12 months.
SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BEAM (100) in the null industry. This means that SYRE’s stock grew similarly to BEAM’s over the last 12 months.
BEAM's SMR Rating (92) in the null industry is in the same range as SYRE (96) in the Pharmaceuticals Major industry. This means that BEAM’s stock grew similarly to SYRE’s over the last 12 months.
SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for BEAM (70) in the null industry. This means that SYRE’s stock grew somewhat faster than BEAM’s over the last 12 months.
BEAM's P/E Growth Rating (28) in the null industry is in the same range as SYRE (42) in the Pharmaceuticals Major industry. This means that BEAM’s stock grew similarly to SYRE’s over the last 12 months.
| BEAM | SYRE | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 88% |
| Advances ODDS (%) | 8 days ago 76% | 1 day ago 87% |
| Declines ODDS (%) | 2 days ago 83% | 5 days ago 87% |
| BollingerBands ODDS (%) | N/A | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 2 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).
- BEAM’s FA Score: 2 green, 3 red.
- SYRE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).
- BEAM’s TA Score: 4 bullish, 2 bearish.
- SYRE’s TA Score: 5 bullish, 3 bearish.
Price Growth
BEAM (@Biotechnology) experienced а -0.12% price change this week, while SYRE (@Biotechnology) price change was +8.36% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.
Reported Earning Dates
BEAM is expected to report earnings on Nov 03, 2026.
SYRE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-1.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SYRE and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.
| Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
|---|---|---|---|---|
| SYRE | 100% | +6.60% | ||
| ORKA - SYRE | 51% Loosely correlated | +6.07% | ||
| PHVS - SYRE | 45% Loosely correlated | +1.30% | ||
| BEAM - SYRE | 45% Loosely correlated | +4.67% | ||
| IMVT - SYRE | 44% Loosely correlated | +2.52% | ||
| PMN - SYRE | 44% Loosely correlated | +20.25% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TSXU | 49.98 | 2.24 | +4.69% |
| Direxion Daily Semiconductors Top 5 Bull 2X ETF (TSXU) | |||
| MTUM | 299.53 | 4.97 | +1.69% |
| iShares MSCI USA Momentum Factor ETF (MTUM) | |||
| JDVI | 39.38 | 0.32 | +0.83% |
| John Hancock Disciplined Value International Select ETF (JDVI) | |||
| PBOC | 31.64 | 0.11 | +0.36% |
| PGIM S&P 500 Buffer 20 ETF - October (PBOC) | |||
| GUSH | 49.83 | -2.42 | -4.63% |
| Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X ETF (GUSH) | |||